• May 3, 2014  

    Pfizer made a $106 billion bid for the British drug maker AstraZeneca this week in a move that was potentially motivated by lower corporate tax rates overseas. The deal could also affect the development of new drugs. Hari Sreenivasan speaks with Bloomberg news reporter Shannon Pettypiece about how mergers affect drug research. Continue reading